This category includes several agents, with at least five key options: bisphosphonates; monoclonal antibodies targeting the Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL), such as Denosumab, which are considered as a first-line treatment for osteoporosis; estrogens; selective estrogen receptor modulators; and calcitonin [22]. Here, TNFSF11 is linked to osteoporosis.